CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 52 enrolled
Drug / intervention
Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04526886
NCT04526886N/ACompleted
CompareCT.gov

A Pragmatic, Single-Arm Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy

Dartmouth-Hitchcock Medical Center·interventional·Posted Aug 26, 2020·Updated Oct 6, 2025

In Brief

A clinical study evaluating Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy for Colorectal Cancer and 5 related conditions. Completed, enrolled 52 participants across 1 site.

Detailed Summary

The study is testing an intervention of an investigator-developed chemotherapy dose adjustment algorithm. The primary objective of this study is to evaluate the effectiveness of the chemotherapy dose adjustment algorithm for reducing unplanned delays in patients receiving FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)-type chemotherapy, while maintaining acceptable chemotherapy dose-intensity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Gastric Cancer, Esophageal Cancer, Ampullary Cancer, Small Bowel Cancer, Appendix Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 26, 2020
Enrollment StartOct 15, 2020
Primary CompletionMar 7, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.9 years ago

Interventions

Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapyother

Chemotherapy dose-adjustment algorithm for FOLFOX chemotherapy